New COVID-19 infections continue to surge around the world, with the U.S., Europe, India, Russia, and Latin America bearing the most daily cases. The severity of illness in the current surge was initially low, but as numbers mount, so too have hospitalisations, intensive care unit (ICU) admissions and deaths. Severe respiratory failure requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) has been the major cause of death throughout the pandemic, though shock, kidney failure and sudden cardiac death are also common complications. Intravenous dexamethasone, as a treatment of virus-induced inflammation, is the only therapy shown to improve mortality in mechanically ventilated patients, from 41% to 29%, in the U.K. RECOVERY study. However, that one in every three to every four people still die despite dexamethasone highlights the complexity of COVID-19 infection and the need for additional therapies.
Inflammation is the bodys normal adaptive response to injury and infection. However, every year, millions of people die from complications of severe, uncontrolled inflammation triggered by common life-threatening conditions such as infection and sepsis, influenza, trauma, surgical complications, liver failure, burn injury, and many others. This inflammation is often driven by a cytokine storm, or the excessive production of cytokines a class of more than 100 different immune system messengers that normally regulate and activate the immune response. Left unchecked, this cytokine storm and the inflammation that ensues, can rapidly kill cells and damage vital organs like the lungs, heart and kidneys, often leading to organ failure and death. In fact, organ failure is responsible for nearly half of all deaths in the intensive care unit (ICU), and has made sepsis (the overzealous immune response to an infection) the #1 killer worldwide, contributing to one in every five deaths each year.
In COVID-19 infection, aggressive hyperinflammation has been directly correlated with greater lung injury and other complications, the need for mechanical ventilation and the risk of death. It is believed that hyperinflammation and damage to the blood vessels in the lungs play an important role in this tale of two types of lung injury. On one hand, cytokine storm and other inflammatory toxins can cause a breakdown in the integrity of blood vessels in the lung. This allows fluid and cells from the bloodstream to flood the delicate air sacs of the lung, essentially drowning the patient from the inside out. At autopsy, this fluid has led to wet, heavy lungs that are four times the weight of normal lungs.
On the other hand, damage to the blood vessel wall from viral infection, cytokine storm, and likely other inflammatory toxins is thought to lead to a clotting cascade, where the delicate balance between bleeding and clotting is tipped in favour of clotting. In this hypercoagulable state, blood clots can form in large veins that often travel to the lungs, resulting in pulmonary emboli, while blood clots also form in tiny blood vessels of the lungs and other organs, leading to a compromise of blood and oxygen delivery, resulting in widespread organ damage. In the lungs, these clots can prevent blood from reaching the air sacs of the lung, resulting in low oxygen levels in the blood. Many critically ill patients exhibit both pathologies, resulting in an unusually severe acute respiratory distress syndrome (ARDS) and hypoxia that many had not seen before.
CytoSorb is a powerful broad-spectrum blood purification cartridge approved in the European Union, manufactured in the U.S., and distributed in 66 countries worldwide, to reduce cytokine storm and other inflammatory toxins or evil humors that can otherwise cause uncontrolled massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet few if any effective treatments exist. CytoSorb has now been used in more than 110,000 human treatments to date across critical care and cardiac surgery, establishing itself as a leading therapy to safely treat cytokine storm and its complications.
Within each CytoSorb cartridge are hundreds of thousands of tiny porous polymer beads, roughly the size of a grain of salt. Each of these beads has millions of pores and channels that allow the bead to act like a tiny sponge and remove cytokines and other inflammatory mediators of a certain size. Treatment is very simple: a temporary dialysis catheter is placed into a major vein, blood is pumped out of the body by a standard dialysis or ECMO machine found in ICUs around the world, through the CytoSorb cartridge where cytokines and other toxins are removed, and the purified blood is then recirculated back into the patient over and over again. A single cartridge can treat a patients entire blood volume more than 70 times in a day, with a new cartridge used each day. Most patients require one to five cartridges, depending on the illness.
Although CytoSorb is used in many different life-threatening conditions, one of the most pressing needs is to help critically ill patients with organ failure complications in severe COVID-19 infection. The rationale of using CytoSorb in these patients is to help remove the circulating inflammatory toxins generated by SARS-CoV-2 viral infection that are continuously damaging the lung, ultimately giving the lungs a chance to heal. We believe this healing is the key to helping patients wean from mechanical ventilation and extracorporeal membrane oxygenation (ECMO) faster.
CytoSorb has already been used to help treat more than 3,000 critically-ill COVID-19 patients across more than 30 countries. When used early and aggressively, CytoSorb has demonstrated a consistent ability to reduce inflammatory mediators, reverse shock, and to help improve lung function and weaning of COVID-19 patients from mechanical lung support in case series that have been published or presented at conferences.
In April 2020, CytoSorb received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure, with many U.S. hospitals now using the therapy. We are currently collecting U.S. treatment data with our CTC COVID-19 registry. CytoSorb has also been included in national COVID-19 treatment guidelines in many countries around the world.
In addition to cytokine adsorption, CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and the antithrombotic drugs, ticagrelor (Brilinta or Brilique) and rivaroxaban (Xarelto), during urgent and emergent cardiothoracic surgery. CytoSorb has also been granted U.S. FDA Breakthrough Designation for the removal of ticagrelor during emergent and urgent cardiothoracic surgery.
CytoSorbents technologies have received non-dilutive grant, contract, and other funding of more than $38 million from the U.S. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the Defense Advanced Research Projects Agency (DARPA), the U.S. Department of Health and Human Services, the U.S. Army, Air Force, Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY, CytoSorb-XL, HemoDefend-RBC, HemoDefend-BGA, VetResQ, K+ontrol,
ContrastSorb, DrugSorb, and others. For more information, please visit the Companys websites at http://www.cytosorbents.com and http://www.cytosorb.com, or follow us on Facebook and Twitter.
*Please note: This is a commercial profile
Follow this link:
Removal of inflammatory 'evil humors' - the key to treating COVID-19 complications? - Open Access Government
- Home - MedStar Heart & Vascular Institute - April 16th, 2018 [April 16th, 2018]
- Guidelines for Standards in Cardiac Surgery - April 16th, 2018 [April 16th, 2018]
- Cardiac Surgery - University of Ottawa Heart Institute - June 16th, 2018 [June 16th, 2018]
- Cardiac Surgery | UNC Medical Center, Hospitals Chapel ... - June 18th, 2018 [June 18th, 2018]
- Heart Surgery | Seattle Childrens Hospital - June 18th, 2018 [June 18th, 2018]
- Pediatric Cardiac Surgery | CHKD | Norfolk, VA - June 18th, 2018 [June 18th, 2018]
- Cardiac Surgery | McLaren Port Huron - July 4th, 2018 [July 4th, 2018]
- CardioVascular Thoracic Institute (CVTI) | The most ... - July 23rd, 2018 [July 23rd, 2018]
- Top Cardiac Surgery COST in India| Benefit - IndianHealthGuru - July 27th, 2018 [July 27th, 2018]
- Cardiac Surgery - Atrial Septal Defect - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery | Stony Brook Medicine - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery in the Adult Fifth Edition: Lawrence H. Cohn ... - August 6th, 2018 [August 6th, 2018]
- Pioneers of Cardiac Surgery: 9780826515940: Medicine & Health ... - August 6th, 2018 [August 6th, 2018]
- Cardiovascular Surgery Department | Cleveland Clinic - August 6th, 2018 [August 6th, 2018]
- Cardiac Surgery - Massachusetts General Hospital, Boston, MA - September 19th, 2018 [September 19th, 2018]
- Cardiac Surgery | Surgery | UC Cincinnati College of ... - September 25th, 2018 [September 25th, 2018]
- Cardiothoracic surgery - Wikipedia - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery | NorthShore - September 25th, 2018 [September 25th, 2018]
- Open Heart Surgery - Cardiac Surgery - University of ... - September 25th, 2018 [September 25th, 2018]
- Heart Surgery | Cleveland Clinic - September 25th, 2018 [September 25th, 2018]
- Cardiac Surgery - Ventricular Assist Devices (VAD) - October 4th, 2018 [October 4th, 2018]
- VCSQI | Virginia Cardiac Services Quality Initiative ... - October 12th, 2018 [October 12th, 2018]
- Cardiac Surgery | Boston Medical Center - October 15th, 2018 [October 15th, 2018]
- Cardiac Surgery | WVU Heart and Vascular Institute - November 10th, 2018 [November 10th, 2018]
- Cardiac Surgery - Heart Valve, Bypass | GW Hospital - November 13th, 2018 [November 13th, 2018]
- Cardiac Surgery - Department of Surgery - University of ... - November 29th, 2018 [November 29th, 2018]
- Cardiac Surgery - Jersey Shore University Medical Center - December 7th, 2018 [December 7th, 2018]
- Blunt Cardiac Injury - The American Association for the ... - December 20th, 2018 [December 20th, 2018]
- Minimally invasive cardiac surgery - Wikipedia - December 20th, 2018 [December 20th, 2018]
- Heart Surgery | Private cardiac specialists in London ... - December 20th, 2018 [December 20th, 2018]
- Cardiac Surgery - Waterbury Hospital - December 20th, 2018 [December 20th, 2018]
- Cardiac surgery - Wikipedia - December 25th, 2018 [December 25th, 2018]
- Heart Surgery | Memorial Healthcare System - December 31st, 2018 [December 31st, 2018]
- A Step-By-Step Look at Open Heart Bypass Surgery - December 31st, 2018 [December 31st, 2018]
- Cardiac Surgery - Erlanger - December 31st, 2018 [December 31st, 2018]
- Inova Cardiac and Thoracic Surgery | Northern VA & DC - Inova - March 6th, 2019 [March 6th, 2019]
- Cardiac Surgery | Heart and Vascular Center | Dartmouth ... - March 13th, 2019 [March 13th, 2019]
- Cardiovascular Medicine and Cardiac Surgery - April 1st, 2019 [April 1st, 2019]
- Minimally invasive heart surgery - Mayo Clinic - April 3rd, 2019 [April 3rd, 2019]
- Home > Cardiac Surgery | Surgery | Yale School of Medicine - April 16th, 2019 [April 16th, 2019]
- Heart and Vascular Care Services - UR Medicine, University ... - April 18th, 2019 [April 18th, 2019]
- Welcome! | LHSC - April 20th, 2019 [April 20th, 2019]
- Cardiac Surgery | Department of Surgery | The University ... - April 20th, 2019 [April 20th, 2019]
- Coronary bypass surgery - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiovascular Surgery - Overview - Mayo Clinic - April 23rd, 2019 [April 23rd, 2019]
- Cardiac Surgery | McLaren Health Care - April 23rd, 2019 [April 23rd, 2019]
- Volunteer opens heart to his faith after healing cardiac ... - April 23rd, 2019 [April 23rd, 2019]
- Heart Surgery - UChicago Medicine - April 27th, 2019 [April 27th, 2019]
- Heart Surgery | UM St. Joseph Medical Center - May 13th, 2019 [May 13th, 2019]
- Cardiac Surgery - Billings Clinic - May 13th, 2019 [May 13th, 2019]
- Cardiology and Cardiac Surgery - Chicago Cardiologists and ... - May 23rd, 2019 [May 23rd, 2019]
- Cardiac Surgery | Michigan Medicine | University of Michigan - September 11th, 2019 [September 11th, 2019]
- Guidelines for Perioperative Care in Cardiac Surgery ... - September 11th, 2019 [September 11th, 2019]
- Cannula Market To Flourish And Reach USD 433 Million By 2025 - ZMR News Network - October 4th, 2019 [October 4th, 2019]
- Heart Health: Dr Panda says one should never give up on a patient - Republic World - October 4th, 2019 [October 4th, 2019]
- Minimally Invasive Surgery Market 2024 By Manufacturers, Investment Feasibility, Cost Structure And Swot Analysis - The Washington Observer - October 4th, 2019 [October 4th, 2019]
- Michael Schumacher health latest: What is stem cell therapy and how will it help Schumi? - Express.co.uk - October 4th, 2019 [October 4th, 2019]
- Cooperative insurance: Novel financing model aims to deliver healthcare to the middle-class segment - The Hindu BusinessLine - October 4th, 2019 [October 4th, 2019]
- Optimism Linked to Lower Risk of Cardiovascular Events and Death - Cath Lab Digest - October 4th, 2019 [October 4th, 2019]
- Global Cardiac Surgery Devices Market 2019 Innovative Trends and Insights Research upto 2024 - Markets Gazette - October 4th, 2019 [October 4th, 2019]
- Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist - Diagnostic and Interventional Cardiology - October 4th, 2019 [October 4th, 2019]
- Economics of Cochlear Implant Utilization : The Hearing Journal - LWW Journals - October 4th, 2019 [October 4th, 2019]
- How to Keep the Weight Off After Bariatric Surgery - Health Essentials from Cleveland Clinic - October 4th, 2019 [October 4th, 2019]
- Heart Lung Machine Market to Upsurge at 6.13% CAGR by 2023, Owing to Increasing Demand From the Healthcare Sector: Radiant Insights, Inc. - PRNewswire - October 4th, 2019 [October 4th, 2019]
- Annadale toddler born with rare condition is fighting for her life - SILive.com - October 4th, 2019 [October 4th, 2019]
- Ocala Health earns distinction, ranks among top within HCA open heart programs - Ocala News - October 4th, 2019 [October 4th, 2019]
- External Validation Of The Surgical Mortality Probability Model (S-MPM | TCRM - Dove Medical Press - October 4th, 2019 [October 4th, 2019]
- CytoSorb Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac... - October 4th, 2019 [October 4th, 2019]
- Transcatheter Tricuspid Fix Bests Meds Alone in Early Results - Medscape - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183393 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Complicated surgery at NICVD saves life of nine-year-old boy - The News International - October 15th, 2019 [October 15th, 2019]
- Angion Announces Several Strategic Additions to its Management Team to Support the Future Development and Commercialization of ANG-3777 - Yahoo... - October 15th, 2019 [October 15th, 2019]
- 'Sky is the limit' for heart treatment without invasive surgery - Ottawa Citizen - October 15th, 2019 [October 15th, 2019]
- Executive Profile: Dr. David Anschel - Long Island Business News - October 15th, 2019 [October 15th, 2019]
- Heart surgeon and author reveals how he once set fire to patient - The Guardian - October 15th, 2019 [October 15th, 2019]
- Demolition paves way for heart, vascular center - Midland Daily News - October 15th, 2019 [October 15th, 2019]
- The basics of research | TNS - The News on Sunday - October 15th, 2019 [October 15th, 2019]
- Senior Lecturer/Associate Professor in Medical Statistics job with UNIVERSITY OF BRISTOL | 183345 - Times Higher Education (THE) - October 15th, 2019 [October 15th, 2019]
- Sparks, Accusations Fly Over Conduct of EXCEL Trial - Medscape - October 15th, 2019 [October 15th, 2019]
- More Heart Valve Patients May Choose Minimally Invasive Procedure - Newswise - October 15th, 2019 [October 15th, 2019]